ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-SIRPalpha Monoclonal Antibody BYON4228

Also written as “BYON4228 + Rituximab” and “BYON4228 + Pembrolizumab”.

Its studies are mostly in Lymphoma, Non-Hodgkin, led by Byondis.

Furthest: phase 1, since Feb 8, 20232 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Byondis22 open or runningphase 1since Feb 8, 2023Feb 8, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 8, 2023First study: phase 1 study in LymphomaFirst studyNCT05737628 · 17 enrolled · Italy, Netherlands, Spain and more
  2. Apr 10, 2025Phase 1 study in Solid TumorNCT06932952 · 7 enrolled · Belgium, Spain, United Kingdom

TargetBeta

SIRPA →read by rule
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), ”NCIt, by rule

Other programs on SIRPA

ProgramCompanyFurthest phaseStudies
Anti-SIRPa Monoclonal Antibody BI 770371ruleBoehringer Ingelheimphase 24
Anti-SIRPa Monoclonal Antibody DS-1103ruleDaiichi Sankyophase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06932952Solid Tumor · Belgium, Spain, United Kingdom1Active, not recruitingApr 20267
NCT05737628Lymphoma · Italy, Netherlands, Spain and more1Active, not recruitingFeb 202617

How it is read

Names in the registry

  • “BYON4228 + Rituximab”, 1 entry
  • “BYON4228 + Pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.